Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
| ▸ | ARG1 | P05089 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414249 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL10956783 | 1.00 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| Hydrochloric Acid SCHEMBL7375378 | 0.98 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL7455945 | 0.95 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL8083651 | 0.95 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL1819249 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL1052527 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL14828670 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL1052525 | 0.87 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL11234764 | 0.87 | HRH3 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914068-A1 | COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS | Spogen Biotech Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| WO-2020154387-A1 | COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS | SPOGEN BIOTECH INC. (US) | 2020-07-30 | — | — | WO | claimed |
| CN-109219592-A | Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2019-01-15 | — | — | CN | claimed |
| CN-108148113-A | A kind of solid phase synthesis process of nmda receptor adjusting control agent tetrapeptide derivative | 深圳先进技术研究院 | 2018-06-12 | — | — | CN | claimed |
| CN-107417572-A | Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2017-12-01 | — | — | CN | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4696334-A2 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12514938-B2 | Fibroblast activation protein targeting peptides | PERSPECTIVE THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-1554274-A1 | 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004037818-A1 | 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-4499287-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4456761-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-06-26 | — | — | US | disclosed |
| US-4356182-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4291040-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | SLC6A2 2940/4885SLC6A4 3233/4885SLC6A3 3023/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | SLC6A2 2907/4885SLC6A4 2324/4885SLC6A3 3157/4885 |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | MC1R, MC3R, MC5R | SLC6A2 155/4885SLC6A4 137/4885SLC6A3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.